Navigation Links
Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
Date:5/21/2008

nefits.

Investor Q&A Session

United Therapeutics will host an investor Q&A session following the conclusion of the ATS conference at The Westin Harbour Castle, One Harbour Square, Toronto, Ontario, on May 21, 2008, at 5:00 pm EDT. Vallerie McLaughlin, MD, Director of the Pulmonary Hypertension Program at the University of Michigan, will join United Therapeutics' senior management in this Q&A session, which is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.

About Remodulin

Remodulin is indicated for the treatment of PAH in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion; however, because of the risks associated with chronic indwelling central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who are intolerant of the subcutaneous route, or in whom these risks are considered warranted.

Remodulin is indicated to diminish the rate of clinical deterioration in patients requiring transition from Flolan(R); the risks and benefits of each drug should be carefully considered prior to transition.

Important Safety Information

Chronic intravenous infusions of Remodulin are delivered using an indwelling central venous catheter. This route is associated with the risk of blood stream infections (BSI) and sepsis, which may be fatal. Remodulin is contraindicated in patients with hypersensitivity to Remodulin, its ingredients, or similar drugs. Remodulin is a potent vasodilator. It lowers blood pressure, which may be further lowered by other drugs that also reduce blood pressure. Remodulin inhibits platelet aggregation and therefore, may increase the risk of bleeding, particularly in patients on anticoagulants
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Treprostinil Data to be Presented at Annual Meeting of the American Thoracic Society
2. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
3. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
4. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
5. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
6. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
7. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
8. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
9. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
10. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
11. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)... 2014 The Cadence Fitness & Health Center has ... Medical Fitness Association, a non-profit organization assisting medically integrated ... The Cadence Fitness & Health Center is the only ... in the Chicagoland area. "The certification means ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
(Date:7/9/2014)... signals active in almost all types of cancer sends ... may help fuel a tumour,s uncontrolled growth, new research ... London, identified a molecular trigger responsible for ratcheting up ... factory that makes the building blocks cancer cells need ... signalling pathway, called SREBP, controls the flow of messages ...
(Date:7/9/2014)... PROVIDENCE, R.I. Researchers have found that fecal ... difficile in immunocompromised patients. This is the result ... gastroenterologist in the Center for Women,s Gastrointestinal Medicine at ... have been published online in advance of print in ... Clostridium difficile , or C. diff , has ...
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... Institute of Allergy and Infectious Diseases (NIAID), part ... an early-stage clinical trial of CRS3123, an investigational ... ( C. difficile ) infection. CRS3123 (previously ... inhibits C. difficile growth while sparing normal intestinal ... up to 30 healthy men and women ages ...
(Date:7/9/2014)... , , , , , ... , , , , ... assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , ... , , , , , , ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), a ... products, is scheduled,to announce its financial results for ... 2008, before the market opens. At 9:00 a.m. ... conference call to review the,Company,s third quarter financial ...
... The American Fertility Association,introduces Manicures and Martinis, ... women together in a casual setting over manicures ... preserving fertility. It,s,free, relaxing, fun, and educational. The ... hosted by leading professionals in the reproductive medical,field, ...
... TUCSON, Ariz., Oct. 30 NaturalNews.com, the ... one million health-conscious,consumers, has posted audio interviews ... of "Home Safe Home," and Byron Richards, ... nutritional supplement,provider. Both interviews are available as ...
... One of the Top 10 Most Interesting Metabolic ... 30 Genaera,Corporation (NASDAQ: GENR ) will ... held November 3-5 at the Lowes Hotel in,Philadelphia, ... Scientific Officer, will provide an overview on MSI-1436 ...
... are adjusted , , WEDNESDAY, Oct. 29 (HealthDay News) -- The ... it may pose problems more serious than adjusting sleep patterns. ... of heart attacks following the semi-annual one-hour time changes, although ... very first study on this topic and further studies are ...
... - Nuvo Research Inc.,(TSX: NRI), a Canadian drug development ... that are delivered to and through the skin,using its ... and operational results for the three and nine,months ended ... - The Company remains on target to ...
Cached Medicine News:Health News:MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results 2Health News:The American Fertility Association Announces Plan to Help Young Women Preserve Fertility 2Health News:NaturalNews Posts Audio Interview with Consumer Chemical Expert Debra Lynn Dadd on Bisphenol-A 2Health News:Genaera to Present at Therapeutic Area Partnerships 2008 2Health News:Semi-Annual Time Changes May Affect the Heart 2Health News:Semi-Annual Time Changes May Affect the Heart 3Health News:NUVO announces third quarter 2008 financial results 2Health News:NUVO announces third quarter 2008 financial results 3Health News:NUVO announces third quarter 2008 financial results 4Health News:NUVO announces third quarter 2008 financial results 5Health News:NUVO announces third quarter 2008 financial results 6Health News:NUVO announces third quarter 2008 financial results 7Health News:NUVO announces third quarter 2008 financial results 8Health News:NUVO announces third quarter 2008 financial results 9Health News:NUVO announces third quarter 2008 financial results 10Health News:NUVO announces third quarter 2008 financial results 11Health News:NUVO announces third quarter 2008 financial results 12Health News:NUVO announces third quarter 2008 financial results 13Health News:NUVO announces third quarter 2008 financial results 14Health News:NUVO announces third quarter 2008 financial results 15
... The Vibratome 1500 Sectioning System provides a ... animal, or plant tissues. The 1500 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
... The original Vibratome Semi-Automatic Tissue Sectioning ... rock solid tissue sectioning system. Researchers from ... Vibratome 1000 Classic for their fresh and ... 20 years. With the Vibratome ...
... Vibratome 3000 Plus Sectioning System provides a ... animal, or plant tissues. The 3000 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
... Sectioning System provides a versatile means of ... tissues. The 1500 employs a vibrating ... or embedding. The creation of artifacts, ... enzyme activities, and other deleterious effect inherent ...
Medicine Products: